Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diane Lucente

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 14, 2020
Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohortMelanie T Gentry, Maria I Lapid, Jeremy Syrjanen, et al.
Neurobiology of Aging|October 5, 2019
Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriersQin Chen, Bradley F Boeve, Christopher G Schwarz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Utility of the global CDR<sup>®</sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS ConsortiumToji Miyagawa, Danielle Brushaber, Jeremy Syrjanen, et al.
Nature Genetics|January 10, 2017
SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndromeNatalie D Shaw, Harrison Brand, Zachary A Kupchinsky, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 25, 2019
Nonlinear Z-score modeling for improved detection of cognitive abnormalityJohn Kornak, Julie Fields, Walter Kremers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2019
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degenerationAdam M Staffaroni, Yann Cobigo, Sheng-Yang M Goh, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpointAdam M Staffaroni, Lynn Bajorek, Kaitlin B Casaletto, et al.
Nature Medicine|September 22, 2022
Temporal order of clinical and biomarker changes in familial frontotemporal dementiaAdam M Staffaroni, Melanie Quintana, Barbara Wendelberger, et al.
The Lancet. Neurology|December 8, 2019
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort studyKatrina M Moore, Jennifer Nicholas, Murray Grossman, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2026
Clinical, <i>in vitro,</i> and <i>in vivo</i> evidence of <i>WAPL</i> as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 14, 2020
Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohortMelanie T Gentry, Maria I Lapid, Jeremy Syrjanen, et al.
Neurobiology of Aging|October 5, 2019
Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriersQin Chen, Bradley F Boeve, Christopher G Schwarz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Utility of the global CDR<sup>®</sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS ConsortiumToji Miyagawa, Danielle Brushaber, Jeremy Syrjanen, et al.
Nature Genetics|January 10, 2017
SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndromeNatalie D Shaw, Harrison Brand, Zachary A Kupchinsky, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 25, 2019
Nonlinear Z-score modeling for improved detection of cognitive abnormalityJohn Kornak, Julie Fields, Walter Kremers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2019
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degenerationAdam M Staffaroni, Yann Cobigo, Sheng-Yang M Goh, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpointAdam M Staffaroni, Lynn Bajorek, Kaitlin B Casaletto, et al.
Nature Medicine|September 22, 2022
Temporal order of clinical and biomarker changes in familial frontotemporal dementiaAdam M Staffaroni, Melanie Quintana, Barbara Wendelberger, et al.
The Lancet. Neurology|December 8, 2019
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort studyKatrina M Moore, Jennifer Nicholas, Murray Grossman, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2026
Clinical, <i>in vitro,</i> and <i>in vivo</i> evidence of <i>WAPL</i> as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
Pageof 6